Latest News

STAT Plus: Bluebird’s gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate

Bluebird Bio (BLUE) won’t be selling the world’s most expensive drug. The second priciest? Yup.

Zynteglo, the one-and-done gene therapy for beta thalassemia newly approved in Europe, will carry a price tag of $1.8 million, Bluebird announced Friday. Only Zolgensma, the Novartis gene therapy for spinal muscular atrophy, is priced higher, at $2.1 million.

Continue to STAT Plus to read the full story…

Source link

Related posts

UAB researchers find key role for IgG autoantibodies in IgA nephropathy


Banyan Biomarkers宣布在《柳叶刀杂志神经科分册》上发表ALERT-TBI临床研究结果


Global Cell Separation Market to Grow by USD 7.12 Billion During 2020-2024 | Evolving Opportunities with Akadeum Life Sciences and Becton, Dickinson and Co. | Technavio


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy